Column

Viewpoint

Overcoming the Political and Economic Roadblocks Stopping Effective Comparative Drug Evaluation

12/14/2015

Roger Longman, MA

Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of the resistance of drug companies and payers, stakeholders are finding other tools to help...

...

12/14/2015

Journal of Clinical Pathways

Clinical Pathways GPS

The Place for Biosimilars in Clinical Pathways

12/14/2015

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...

Payers...

12/14/2015

Journal of Clinical Pathways

Editor's Page

Clinical Pathways: Going Beyond Oncology

12/11/2015

Winston Wong, PharmD, Editor-in-Chief

Clinical pathways are most often associated with their use in oncology—specifying which drug to use for the treatment of which type of cancer. Yet, they have the potential to extend far beyond that. They can include...

...

12/11/2015

Journal of Clinical Pathways

Viewpoint

The Current Cost of Cancer Drugs: Physician, Payer and Government Concerns Grow

10/27/2015

Gary Owens, MD

The August 2015 edition of the Mayo Clinic Proceedings featured an article entitled, “In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs”.1 In that article, the authors...

The...

10/27/2015

Journal of Clinical Pathways

Counterpoint

To Increase Innovation and Make Drugs More Affordable, Deregulate

10/27/2015

David R. Henderson, PhD

Charles L. Hooper, MS

Are there ways to make drugs more affordable without reducing the incentive to innovate? Dr. Owens makes two principal claims with which we agree. Any dialogue about the rising cost of cancer drugs must, as the...

Are...

10/27/2015

Journal of Clinical Pathways

Editor's Page

Welcome to Journal of Clinical Pathways

10/27/2015

Winston Wong, PharmD, Editor-in-Chief

We are excited to bring to you Journal of Clinical Pathways, which will serve as a forum for the exciting exchange of data, research, insights, and perspectives that will shape the foundation of value-based care.

We are excited to bring to you...

10/27/2015

Journal of Clinical Pathways

Editor's Page

Meet the Board

08/14/2015

JCP Editors

To lead the Journal of Clinical Pathways is a diverse board of 14 distinguished professionals within the health care sector committed to enhancing the discussion of value-based...

To...

08/14/2015

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products